AstraZeneca’s Antiplatelet Agent Brilinta Superior To Plavix In Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
But Lilly/Daiichi’s pending Effient has done the same thing, albeit with increased bleeding. Full PLATO data, to be released in August, will be scrutinized for safety.